| 3.57 0.33 (10.19%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.42  |
1-year : | 5.16 |
| Resists | First : | 3.78 |
Second : | 4.42 |
| Pivot price | 2.26 |
|||
| Supports | First : | 2.48 |
Second : | 1.67 |
| MAs | MA(5) : | 2.89 |
MA(20) : | 2.15 |
| MA(100) : | 1.91 |
MA(250) : | 8.13  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 91.7 |
D(3) : | 90.7 |
| RSI | RSI(14): 88.9 |
|||
| 52-week | High : | 53.16 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QTTB ] has closed above the upper band by 10.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 197.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.79 - 3.8 | 3.8 - 3.81 |
| Low: | 3.37 - 3.38 | 3.38 - 3.39 |
| Close: | 3.55 - 3.57 | 3.57 - 3.59 |
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Sat, 04 Oct 2025
Q32 Bio Inc.’s Promising Alopecia Areata Treatment Trial Update - MSN
Fri, 29 Aug 2025
Q32 Bio Inc. Stock (QTTB) Opinions on Wells Fargo Healthcare Conference Participation - Quiver Quantitative
Thu, 28 Aug 2025
Alopecia Areata Treatment Developer Q32 Bio to Showcase Pipeline at Wells Fargo Healthcare Conference - Stock Titan
Wed, 06 Aug 2025
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Thu, 08 May 2025
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Tue, 08 Apr 2025
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 69.5 (%) |
| Shares Short | 288 (K) |
| Shares Short P.Month | 356 (K) |
| EPS | -4.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36 % |
| Return on Equity (ttm) | -491.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.95 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | -3.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|